Biogen investors got a much-needed pleasant surprise this holiday season.
The company announced late last week it had received approval from the Food and Drug Administration for Spinraza. The drug is the first treatment for a rare disease known as spinal muscular atrophy, and the FDA approved it for usage in a broad range of patients.
The approval is welcome news for shareholders and incoming Chief Executive Michel Vounatsos, and the good news came early.
